A dedicated nurse-led service for antipsychotic-induced weight gain

Ohlsen, Ruth; Treasure, Janet; Pilowsky, Lyn S.

doi:10.1192/pb.28.5.164

Cited by 12 publications

(21 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, another naturalistic study showed no significant outcomes following a similar nurse-led programme in patients with schizophrenia spectrum disorders [Ohlsen et al 2004].…”

Section: Description and Discussion Of Studiesmentioning

confidence: 99%

Interventions for the metabolic syndrome in schizophrenia: a review

Papanastasiou¹

2012

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Abstract:The metabolic syndrome (MetS) is an increasingly prevalent condition in people with schizophrenia. It remains highly prevalent in the general population in developed countries, but recently health promotion campaigns and greater awareness of the high associated mortality rates have resulted in improvements in the rates of cardiovascular risk factors. This is not the case for people with schizophrenia who continue to have more than twice the rates of MetS and significantly higher mortality rates than the general population. Various behavioural and pharmacological interventions have been used to improve conditions that are linked to MetS, mainly smoking and obesity. This review aims to provide an update of the latest knowledge about the behavioural, pharmacological and other interventions that might help to combat this life-threatening problem in people with schizophrenia.

show abstract

“…However, another naturalistic study showed no significant outcomes following a similar nurse-led programme in patients with schizophrenia spectrum disorders [Ohlsen et al 2004].…”

Section: Description and Discussion Of Studiesmentioning

confidence: 99%

Interventions for the metabolic syndrome in schizophrenia: a review

Papanastasiou¹

2012

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

show abstract

“…Three studies examined the effects of behavioral modification alone (22,33,37), three studies examined the effects of calorie restriction alone (23,34,39), ten studies examined the effects of psychoeducation alone (21,24,(26)(27)(28)(29)31,32,42,43), four studies examined calorie restriction combined with psychoeducation (25,36) or behavioral modification (35,36,38), and one study examined the effects of behavior modification and psychoeducation (40). The most common forms of behavioral modification used were token economies (22,35,38,40), followed by response cost (33,36) and social reinforcement (37).…”

Section: Overviewmentioning

confidence: 98%

“…Mean duration of treatment was 25.68 weeks, excluding two studies which examined short educational interventions (21,24), and a retrospective study examining self-directed weight loss of varying lengths (30). Six studies included follow-up assessments after termination of treatment (21,24,26,36,42,43), with a mean duration of 41.33 weeks, but a median duration of 8 weeks, due to one study, which had a follow-up period of 3 years (21).…”

Section: Overviewmentioning

confidence: 99%

“…Only 9 studies reported drop-out rates (21,(25)(26)(27)(28)(29)(30)(31)(32) with mean attrition rate of 47.52%, and a range from 9.7% -90%. Ten studies were conducted with inpatient populations (22,23,26,(33)(34)(35)(36)(37)(38)(39), 4 studies were conducted in residential treatment settings (25,40), partial hospitalization (31) or day treatment centers (32), and 9 were conducted with outpatient populations (21,24,(27)(28)(29)(30)(41)(42)(43). Two reports were chart reviews (30,41), 4 were case studies (33,35,37,38), 7 studies utilized a pre-post design (22)(23)(24)(25)(26)28,43), 6 were quasi experimental, using a crossover (34) or case control design (21,…”

Section: Overviewmentioning

confidence: 99%

“…Ten studies were conducted with inpatient populations (22,23,26,(33)(34)(35)(36)(37)(38)(39), 4 studies were conducted in residential treatment settings (25,40), partial hospitalization (31) or day treatment centers (32), and 9 were conducted with outpatient populations (21,24,(27)(28)(29)(30)(41)(42)(43). Two reports were chart reviews (30,41), 4 were case studies (33,35,37,38), 7 studies utilized a pre-post design (22)(23)(24)(25)(26)28,43), 6 were quasi experimental, using a crossover (34) or case control design (21,27,31,32,39), and 4 studies utilized a randomized controlled design (29,36,40,42). Mean duration of treatment was 25.68 weeks, excluding two studies which examined short educational interventions …”

Section: Overviewmentioning

confidence: 99%

See 2 more Smart Citations

A Comprehensive Review of Behavioral Interventions for Weight Management in Schizophrenia

Loh¹,

Meyer²,

Leckband³

2006

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

Much of the literature is anecdotal, methodologically unsound, poorly documented, or applicable only to inpatient settings. Nonetheless, recent data from controlled studies suggest that behavioral interventions in patients diagnosed with schizophrenia may prevent future weight gain, and in some instances promote weight loss. High drop-out rates, and the absence of extended post-treatment follow-up still limit the conclusions regarding general efficacy of behavioral treatment of obesity in patients with schizophrenia.

show abstract

Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review

Leslie

Hankey

Lean

2007

QJM

150

View full text Add to dashboard Cite

Several drugs, or categories of drugs, listed by the WHO and other writers and used in the treatment of chronic disease, are consistently associated with weight gain as a side effect and considered 'obesogenic'. The extent to which they may contribute to the multifactorial process behind obesity is not well documented. We systematically reviewed papers from Medline 1966-2004, Embase 1980-2004, PsycINFO 1967-2004, and Cochrane Register of Controlled Trials, to determine the effect on body weight of some drugs that are believed to favour weight gain. We included randomized controlled studies of adult participants (>18 years) prescribed a drug considered obesogenic, that compared the 'obesogenic' drug with placebo, an alternative drug or other treatment, and that had a duration of at least 3 months: 43 studies totalling 25,663 subjects met these criteria. The main objective of the majority of studies was to compare the efficacy and safety of drug therapy, with weight change recorded under safety outcomes; weight change was a primary outcome measure in only six studies. There was evidence of weight gain for all drugs included, up to 10 kg at 52 weeks. Differences in dosage, patient population, duration of treatment and dietary advice make generalization of the results difficult. Data on body weight are often not recorded in published clinical trials or is reported in insufficient detail. This side-effect has potentially serious consequences, and should be mentioned to patients. Weight management measures should be routinely considered when prescribing drugs known to promote weight gain. Future clinical trials should always document weight changes.

show abstract

A dedicated nurse-led service for antipsychotic-induced weight gain

Cited by 12 publications

References 11 publications

Interventions for the metabolic syndrome in schizophrenia: a review

Interventions for the metabolic syndrome in schizophrenia: a review

A Comprehensive Review of Behavioral Interventions for Weight Management in Schizophrenia

Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review

Contact Info

Product

Resources

About